| Physiological and pharmacological roles of ABCG2 (BCRP): recent findings in Abcg2 knockout mice MLH Vlaming, JS Lagas, AH Schinkel Advanced drug delivery reviews 61 (1), 14-25, 2009 | 319 | 2009 |
| Carcinogen and anticancer drug transport by Mrp2 in vivo: studies using Mrp2 (Abcc2) knockout mice MLH Vlaming, K Mohrmann, E Wagenaar, DR de Waart, RPJO Elferink, ... Journal of Pharmacology and Experimental Therapeutics 318 (1), 319-327, 2006 | 194 | 2006 |
| Differential, strain-specific cellular and subcellular distribution of multidrug transporters in murine choroid plexus and blood–brain barrier A Soontornmalai, MLH Vlaming, JM Fritschy Neuroscience 138 (1), 159-169, 2006 | 169 | 2006 |
| Multidrug resistance proteins 2 and 3 provide alternative routes for hepatic excretion of morphine-glucuronides K van de Wetering, N Zelcer, A Kuil, W Feddema, M Hillebrand, ... Molecular pharmacology 72 (2), 387-394, 2007 | 129 | 2007 |
| Functionally overlapping roles of Abcg2 (Bcrp1) and Abcc2 (Mrp2) in the elimination of methotrexate and its main toxic metabolite 7-hydroxymethotrexate in vivo MLH Vlaming, Z Pala, A van Esch, E Wagenaar, DR de Waart, ... Clinical Cancer Research 15 (9), 3084-3093, 2009 | 117 | 2009 |
| Multidrug resistance protein 2 is an important determinant of paclitaxel pharmacokinetics JS Lagas, ML Vlaming, O van Tellingen, E Wagenaar, RS Jansen, ... Clinical cancer research 12 (20), 6125-6132, 2006 | 113 | 2006 |
| P-glycoprotein (P-gp/Abcb1), Abcc2, and Abcc3 determine the pharmacokinetics of etoposide JS Lagas, L Fan, E Wagenaar, MLH Vlaming, O van Tellingen, JH Beijnen, ... Clinical cancer research 16 (1), 130-140, 2010 | 111 | 2010 |
| Hepatic transport mechanisms of cholyl-L-lysyl-fluorescein DR de Waart, S Häusler, MLH Vlaming, C Kunne, E Hänggi, HJ Gruss, ... Journal of Pharmacology and Experimental Therapeutics 334 (1), 78-86, 2010 | 96 | 2010 |
| Abcc2 (Mrp2), Abcc3 (Mrp3), and Abcg2 (Bcrp1) are the main determinants for rapid elimination of methotrexate and its toxic metabolite 7-hydroxymethotrexate in vivo MLH Vlaming, A van Esch, Z Pala, E Wagenaar, K van de Wetering, ... Molecular cancer therapeutics 8 (12), 3350-3359, 2009 | 88 | 2009 |
| Impact of Abcc2 (Mrp2) and Abcc3 (Mrp3) on the In vivo Elimination of Methotrexate and its Main Toxic Metabolite 7-hydroxymethotrexate MLH Vlaming, Z Pala, A van Esch, E Wagenaar, O van Tellingen, ... Clinical Cancer Research 14 (24), 8152-8160, 2008 | 77 | 2008 |
| Predicting carrier-mediated hepatic disposition of rosuvastatin in man by scaling from individual transfected cell-lines in vitro using absolute transporter protein … S Bosgra, E van de Steeg, ML Vlaming, KC Verhoeckx, MT Huisman, ... European Journal of Pharmaceutical Sciences 65, 156-166, 2014 | 73 | 2014 |
| Pharmacokinetic assessment of multiple ATP-binding cassette transporters: the power of combination knockout mice JS Lagas, MLH Vlaming, AH Schinkel Molecular interventions 9 (3), 136, 2009 | 71 | 2009 |
| Blinded, multicenter evaluation of drug-induced changes in contractility using human-induced pluripotent stem cell-derived cardiomyocytes U Saleem, BJ Van Meer, PA Katili, NAN Mohd Yusof, I Mannhardt, ... Toxicological Sciences 176 (1), 103-123, 2020 | 66 | 2020 |
| Drug-drug interactions between rosuvastatin and oral antidiabetic drugs occurring at the level of OATP1B1 E van de Steeg, R Greupink, M Schreurs, IHG Nooijen, KCM Verhoeckx, ... Drug Metabolism and Disposition 41 (3), 592-601, 2013 | 66 | 2013 |
| Impact of abcc2 [multidrug resistance-associated protein (MRP) 2], abcc3 (MRP3), and abcg2 (breast cancer resistance protein) on the oral pharmacokinetics of methotrexate and … MLH Vlaming, A van Esch, E van de Steeg, Z Pala, E Wagenaar, ... Drug metabolism and disposition 39 (8), 1338-1344, 2011 | 60 | 2011 |
| Comparison of 10 control hPSC lines for drug screening in an engineered heart tissue format I Mannhardt, U Saleem, D Mosqueira, MF Loos, BM Ulmer, MD Lemoine, ... Stem cell reports 15 (4), 983-998, 2020 | 55 | 2020 |
| Breast cancer resistance protein (Bcrp1/Abcg2) is expressed in the harderian gland and mediates transport of conjugated protoporphyrin IX JW Jonker, S Musters, MLH Vlaming, T Plosch, KER Gooijert, ... American Journal of Physiology-Cell Physiology 292 (6), C2204-C2212, 2007 | 43 | 2007 |
| Liquid chromatography–tandem mass spectrometric assay for sorafenib and sorafenib–glucuronide in mouse plasma and liver homogenate and identification of the glucuronide metabolite RW Sparidans, MLH Vlaming, JS Lagas, AH Schinkel, JHM Schellens, ... Journal of Chromatography B 877 (3), 269-276, 2009 | 40 | 2009 |
| Complex pharmacokinetic behavior of ezetimibe depends on abcc2, abcc3, and abcg2 DR de Waart, MLH Vlaming, C Kunne, AH Schinkel, RPJO Elferink Drug metabolism and disposition 37 (8), 1698-1702, 2009 | 36 | 2009 |
| To apply microdosing or not? Recommendations to single out compounds with non-linear pharmacokinetics S Bosgra, MLH Vlaming, WHJ Vaes Clinical pharmacokinetics 55, 1-15, 2016 | 32 | 2016 |
Olaf van TellingenNetherlands Cancer InstituteGeverifieerd e-mailadres voor nki.nl
